Drugs that are given systemically have a wide range of negative effects on the visual system.  Although most risks are unlikely to occur while taking these medications, if visual abnormalities start to appear, the patient should be referred to an eye care specialist for an eye test.

In individuals taking long-term chloroquine or hydroxychloroquine medication, repeated testing for toxic retinopathy is advised. After five years, screening should be performed annually if there are no baseline abnormalities [1].

Patients who take long-term systemic corticosteroids are more likely to develop glaucoma, cataracts, and central serous retinopathy, among other ocular side effects. Prior to commencing corticosteroids, at baseline, and whenever impaired or blurred vision first appears, they should be referred to an eye care specialist for an eye test.

Alpha-adrenoreceptor antagonists, such as tamsulosin, increase the risk of intraoperative floppy iris syndrome, which can make cataract surgery more difficult, hence an ophthalmologist should be told if a patient is taking them prior to cataract surgery [2].

With this brief introduction let us move on to discuss adverse effects on the eye and its adnexa by drugs administered systemically.

Classification

Adverse drug reactions are rationally and clinically classified into two groups.

Group A: Quantitatively abnormal reactions

These effects are the result of the drug's typical, but exaggerated, pharmacological action. These reactions are frequently dose-related and frequently predictable. These negative effects can be controlled by modifying the dose, switching to a drug that is comparable but less likely to have negative effects, or taking additional medications that block the  negative  effects   of  the   original   medication  [3].

Group B: Qualitatively abnormal actions

These reactions are totally abnormal. They have no relation to the drug's normal pharmacology. They are unexpected and unforeseen. These qualitative adverse reactions are due to four causes 

• Genetic: Like erythrocyte glucose-6 phosphate dehydrogenase-G-S-PD enzyme deficiency causing genetically based disorders.

• Immunological or allergic-mediated by immunological mechanism -Stevens ¬Johnson syndrome.

• Teratological-caused by drugs given to mother during pregnancy causing adverse effect on foetus and neonate-like Thalidomide, so-called safe hypnotic was given during pregnancy causing phacomalia or micromalia, anophtbalrnos microphthalmos, colobomata.

• Neoplastic or carcinogenic disorders ¬caused by large number of drugs given unnecessarily and also by drugs given necessarily but for a long period of time-about 10 years [4].

Clinical features

The most prevalent site of medication toxicity, which typically takes the form of dermatitis, inflammation, or an allergic reaction, is the eyelid. 

The predominant symptom of drug-induced kerato conjunctival diseases is conjunctival hyperaemia (red eyes), which may or may not be accompanied by superficial corneal involvement. These negative effects are frequently brought on by the drug preservatives in topical ocular medicines. Botox® therapy for blepharospasm might cause eyelid drooping and corneal exposure. Patients who get tamsulosin treatment and have cataract surgery are susceptible to an adverse medication reaction known as intraoperative floppy iris syndrome [5].

Angle-closure glaucoma can develop as a result of the ciliary body enlargement brought on by several sulfa-based medications. Additionally, in vulnerable patients, adrenergic medications, specific 2-adrenergic agonists, and anticholinergic drugs may cause pupillary dilatation and trigger angle-closure glaucoma. Increased intraocular pressure brought on by the administration of glucocorticoids systemically, topically, or intravitreally is known to make some individuals more prone to developing open-angle glaucoma. The chemotherapy drugs docetaxel and paclitaxel have also been linked to this painless form of glaucoma. The harmful effects of medications taken orally or topically may show themselves as lens cloudiness [6].

Differential diagnosis

Pain should be considered to be inconsistent with conjunctivitis, episcleritis, or blepharitis rather than discomfort. The possibility of a serious cause growing with severity includes keratitis, intraocular or scleral inflammation, or elevated intraocular pressure. Particularly indicative of significantly elevated intraocular pressure are the accompanied nausea and vomiting. Scleritis is characterized by dull, intense pain that frequently wakes the patient up at night. A hallmark symptom of anterior uveitis and keratitis is photophobia.

Management

Due to the difficulties in getting medications to the target tissues in the eye at concentrations high enough to have a therapeutic impact, treating ocular illnesses can be challenging. The primary barriers for delivering medications to treat disorders in the front and posterior sections of the eye, respectively, are the cornea and the blood-retinal barrier, which is made up of the retinal pigment epithelium and the retinal capillaries. The blood-retinal barrier restricts further drug absorption into the eye despite the eye having a rich blood supply and a relatively modest mass. Drugs can diffuse from the systemic blood circulation to the choroid through the fenestrated choroidal blood vessels. Drug distribution can be made more effective with the use of computational methods that predict ocular pharmacokinetics [7].

The eye can have negative side effects from systemic drugs for a variety of illnesses, ranging from asymptomatic lesions to potentially blinding problems like toxic retinopathy and optic neuropathy. The majority of drug-induced eye problems can be avoided or even cured during ophthalmological screening thanks to the early detection of hazardous effects. The main medications in our study are those with frequent and serious ocular side effects. Medical professionals who write prescriptions for drugs must be well aware of the dangers of ocular toxicity and the significance of routine screening [8].

Through the aqueous fluid, limbal vasculature, and tear film, systemic medicines may reach the cornea. The underlying chemical characteristics of medicines frequently cause corneal abnormalities. Amphiphilic drugs (such as amiodarone, chloroquine, suramin, and clofazimine) might cause lipidosis due to the drug and the emergence of a vortex keratopathy. Cytarabine, an antimetabolite, may cause basal epithelial cells to degenerate and produce epithelial microcysts. A stromal or endothelial deposition may also result from drugs and drug metabolites that are taken systemically. Reduced visual acuity, photophobia, and ocular discomfort due to corneal changes are possible side effects, however they usually go away as the medicine is stopped. The likelihood of lenticular or retinal alterations may be reflected in the frequency with which systemic drug manifestations in the cornea are dosage dependent [9].

All layers of the cornea may experience alterations as a result of systemic drugs. Even though corneal deposition is usually not a reason to stop taking a treatment, patients who are taking a certain medication should be watched for symptoms of corneal deposition as well as for indications of irreversible ocular damage.

On the other hand, a single medicine may have an impact on many ocular structures and result in a number of distinct clinical diseases. Clinicians need to be aware of drug-induced ocular problems, whether or not they are mentioned in pharmaceutical package inserts, and should seek advice from an ophthalmologist if they are unsure [10].

1. Mody, D. G. "Adverse Drug Reactions." Indian Journal of Ophthalmology, vol. 30, no. 4, July 1982, p. 257. IJO, https://www.ijo.in/article.asp?issn=0301-4738;year=1 982;volume=30;issue=4;spage=257;epage=260;aulast=Mody. Accessed 25 July 2022.

2. Li, J., et al. "Drug-Induced Ocular Disorders." Drug Safety, vol. 31, no. 2, 3 Jan. 2013, pp. 127–141. Springer, https://link.springer.com/articl e /10.2165/ 00002018-200831020-00003. Accessed 25 July 2022.

3. Izazola-Conde, C., et al "Ocular and Systemic Adverse Effects of Ophthalmic and Non-Ophthalmic Medications." Proceedings of the Western Pharmacology Society, vol. 54, 2011, pp. 68–71. PubMed, https://pubmed.ncb i.nlm.nih.gov/22423585/. Accessed 25 July 2022.

4. Alves, C., et al. "Risk of Ophthalmic Adverse Effects in Patients Treated with MEK Inhibitors: A Systematic Review and Meta-Analysis." Ophthalmic Research, vol. 57, no. 1, 1 Dec. 2017, pp. 60–69. PubMed, https://pubmed.ncbi.nlm.nih. gov /27404571/. Accessed 25 July 2022.

5. Vaughan & Asbury’s General Ophthalmology. 19th ed., McGraw Hill Medical. AccessMedicine, https://access medicine.mh medical.com/book.aspx?boo kID=2186. Accessed 25 July 2022.

6. Pearce, W. A., et al. "Pigmentary Maculopathy Associated with Chronic Exposure to Pentosan Polysulfate Sodium." Ophthalmology, vol. 125, no. 11, 1 Nov. 2018, pp. 1793–1802. PubMed, https://pubmed. ncbi.nlm.nih.gov/29 801663/. Accessed 25 July 2022.

7. Hollander, D. A., et al Aldave. "Drug-Induced Corneal Complications." Current Opinion in Ophthalmology, vol. 15, no. 6, Dec. 2004, pp. 541–548. LWW, https://journals.lww.com/co-ophthalmology/Fulltext/2 0 04/12000/Drug_induced_corneal_complications.12.as px. Accessed 25 July 2022.

8. Vellonen, K. S., et al Urtti. "Prediction of Ocular Drug Distribution from Systemic Blood Circulation." Molecular Pharmaceutics, vol. 13, no. 9, 6 Sept. 2016, pp. 2906–2911.

9. Spiteri, M. A., et al. "Adverse Ocular Reactions to Drugs." Postgraduate Medical Journal, vol. 59, 1983, pp. 343–349.

10. Ghemtio, L., et al "Predictive Modeling of Ocular Pharmacokinetics and Adverse Effects." Current Pharmaceutical Design, vol. 22, no. 46, 28 Sept. 2016, pp. 6928–6934. PubMed, https://pub med.ncbi.nlm .nih.gov/27669964/. Accessed 25 July 2022.